The Patent Finder

Crispr Therapeutics AG

75 patents currently held · Updated Nov 16, 2026
27 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 4 name spellings.

0
Ending by 2030
Dec 2037
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 16, 2026
    The maintenance fee for Methods and Compositions for Treating Cancer (US 11,649,438) comes due Nov 16, 2026. Unpaid by May 17, 2027, it lapses early.
  • 2 fees due Dec 20, 2026
  • 1 fee due Apr 24, 2027
    The maintenance fee for Anti-idiotype antibodies targeting anti-CD70 chimeric antigen receptor (US 11,795,238) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
  • 1 fee due May 28, 2027
    The maintenance fee for Compositions and Methods for Genomic Editing by Insertion of Donor Polynucleotides (US 11,827,877) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
  • 2 fees due Jun 5 to 26, 2027 · next Jun 5
  • 2 fees due Jul 2 to 9, 2027 · next Jul 2
  • 2 fees due Sep 5 to 12, 2027 · next Sep 5

Which patents, and when each one lapses · Pro

Recent changes

  • 3 of the patents on this record were granted since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 12,043,843Materials and Methods for Treatment of Hemoglobinopathies
In force
 · High confidence
In forceHigh confidence
US 11,083,799Materials and Methods for Treatment of Hereditary Haemochromatosis
In force
 · High confidence
In forceHigh confidence
US 12,186,406Materials and Methods for Treatment of Hereditary Haemochromatosis
In force
 · High confidence
In forceHigh confidence
US 10,729,725Materials and Methods for Engineering Cells and Uses Thereof in Immuno-Oncology
In force
 · High confidence
In forceHigh confidence
US 10,736,919Materials and Methods for Engineering Cells and Uses Thereof in Immuno-Oncology
In force
 · High confidence
In forceHigh confidence
US 10,881,689Materials and Methods for Engineering Cells and Uses Thereof in Immuno-Oncology
In force
 · High confidence
In forceHigh confidence
US 11,013,767Materials and Methods for Engineering Cells and Uses Thereof in Immuno-Oncology
In force
 · High confidence
In forceHigh confidence
US 11,071,755Materials and Methods for Engineering Cells and Uses Thereof in Immuno-Oncology
In force
 · High confidence
In forceHigh confidence
US 11,135,247Materials and Methods for Engineering Cells and Uses Thereof in Immuno-Oncology
In force
 · High confidence
In forceHigh confidence
US 11,166,985Materials and Methods for Engineering Cells and Uses Thereof in Immuno-Oncology
In force
 · High confidence
In forceHigh confidence
10 of 75 patents shown.
Pro members see all 75.
Pro members: see all 75 patents
Also on record, not counted in the 75: 27 patents in force now held by others · 3 lapsed for an unpaid fee · 1 past the fee grace period. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

35 pending · 58 abandoned · 13 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited